Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 76,340 shares, an increase of 116.4% from the June 30th total of 35,280 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 93,500 shares, the short-interest ratio is presently 0.8 days.
Otsuka Stock Performance
Shares of OTSKY traded up $0.43 during midday trading on Tuesday, hitting $34.73. 38,070 shares of the stock traded hands, compared to its average volume of 39,845. The business's 50 day moving average price is $34.23 and its two-hundred day moving average price is $33.38. The firm has a market capitalization of $37.31 billion and a PE ratio of 14.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. Otsuka has a 1-year low of $23.50 and a 1-year high of $37.52.
Otsuka (OTCMKTS:OTSKY - Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The company had revenue of $3.96 billion for the quarter, compared to analysts' expectations of $3.78 billion. Equities research analysts predict that Otsuka will post 1.96 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Zacks Research upgraded Otsuka from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Otsuka has an average rating of "Hold".
Check Out Our Latest Research Report on OTSKY
About Otsuka
(
Get Free Report)
Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.
Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Otsuka, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Otsuka wasn't on the list.
While Otsuka currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.